Cancer remains a formidable challenge worldwide, necessitating innovative solutions and the critical need for models that precisely mimic human responses, given the high failure rates in clinical trials. This whitepaper reveals how MIMETAS's pioneering organ-on-a-chip technology and 3D tissue modeling expertise represent a significant advancement in closing the translational gap in cancer drug discovery.
MIMETAS' cancer modeling capabilities are showcased through six case studies, highlighting our ability to model processes such as immune cell migration, CAR T cell efficacy, and the TME's complex interactions, all contributing to drug discovery progress.
Download the whitepaper to learn more!